Relationship between chronotropic incompetence and β-blockers based on changes in chronotropic response during cardiopulmonary exercise testing  by Takano, Nami et al.
IJC Heart & Vasculature 6 (2015) 12–18
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureRelationship between chronotropic incompetence and β-blockers based
on changes in chronotropic response during cardiopulmonary
exercise testing☆Nami Takano a,⁎, Haruhito Takano b, Taira Fukuda c, Hironobu Kikuchi a, Gaku Oguri a, Kazuya Fukumura d,
Kuniaki Iwasawa e, Toshiaki Nakajima d
a Department of Cardiovascular Medicine, The University of Tokyo Hospital, 7-3-1Hongo, Bunkyo-Ku, Tokyo 113-8655, Japan
b Takano Clinic, 4-6-38 Kamisaginomiya, Nakanoku, Tokyo 165-0031, Japan
c Health Center, Hitotsubashi University, 2-1 Naka, Kunitachishi, Tokyo 186-8601, Japan
d Department of Ischemia Circulatory Physiology, The University of Tokyo Hospital, 7-3-1Hongo, Bunkyo-Ku, Tokyo 113-8655, Japan
e Division of Health Service Promotion, University of Tokyo, 7-3-1Hongo, Bunkyo-Ku, Tokyo 113-8655, Japan☆ The authors take responsibility for all aspects of the re
of the data presented and their discussed interpretation.
⁎ Corresponding author. Tel.: +81 3 3815 5411; fax: +
E-mail address: namikubota-circ@umin.ac.jp (N. Taka
http://dx.doi.org/10.1016/j.ijcha.2014.11.002
2352-9067/© 2014 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 27 July 2014
Received in revised form 11 November 2014
Accepted 25 November 2014
Available online 3 December 2014
Keywords:
Chronotropic incompetence
Cardiopulmonary exercise testing
β-blocker
Metabolic chronotropic relationship
Cardiac rehabilitation
Background: Chronotropic incompetence (CI), an attenuated heart rate (HR) response to exercise, is common in
patients with cardiovascular disease. The aim of this study was to assess changes in the chronotropic response
(CR) during cardiopulmonary exercise testing (CPET) in patients undergoing cardiac rehabilitation and investi-
gate the effects of β-blockers.
Methods: Patients undergoing cardiac rehabilitation performed CPET. Failure to achieve 80% of the age-predicted
maximal HR (APMHR) deﬁned CI. Values of themetabolic chronotropic relationship (MCR)were calculated from
the ratio of the HR reserve tometabolic reserve at 4 stages, warm-up (MCR-Wu), anaerobic threshold (MCR-AT),
respiratory compensation (MCR-Rc), and peak point (MCR-Pk), using theWilkoffmodel. In patientswho showed
an increase in MCR at ≥3 of the 4 exercise stages, CR was considered to have improved.
Results: Patients with high BNP levels (≥80 pg/ml) had a lowerMCR at all stages compared with those with low
BNP levels (b80 pg/ml). Of the 80 patients, 47 showed an increase in both peak VO2 and AT, and of these 31
(66.0%) were taking β-blockers. Improvement in CR was observed in 30 of 47 patients with CI, and 70% of
these were taking β-blockers. In patients not taking β-blockers, MCR-AT was lower than MCR-Rc, whereas in
those taking β-blockers MCR-AT was higher than MCR-Rc.
Conclusions:AnattenuatedHR responsemay occur during the early stages of exercise. TheHR response according
to the presence or absence of β-blockers is clearly identiﬁable by comparing MCR-AT and MCR-Rc using the
Wilkoff model.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chronotropic incompetence (CI), an attenuated heart rate (HR)
response to exercise, is associated with increased cardiovascular risk
and overall mortality [1–5]. The prevalence of CI in patients with chron-
ic heart failure (CHF) is between 20% and 70% [6]. The variability is a
result of multiple deﬁnitions, the confounding effects of aging andmed-
ications, and different characteristics of study populations. CI is believed
to reﬂect an underlying autonomic nervous system imbalance involving
various factors and complex interactions [7,8]. HR at rest is regulated byliability and freedom from bias
81 3 3990 2237.
no).
land Ltd. This is an open access articlthe parasympathetic nervous system. In the initial stages of exercise, HR
increases with withdrawal of vagal activity. On commencing exercise,
sympathetic nerve activity increases gradually and becomes dominant
at a stress load greater than the anaerobic threshold (AT). However,
patientswithCHFhave sympathetic overactivitywithβ1-receptor down-
regulation and reduced myocardial sensitivity to β-agonists [9], which
may in turn lead to a reduction in HR response to exercise [7,10,11].
Currently, β-blocker therapy is pivotal in the treatment of heart dis-
ease including chronic ischemic syndromes, acute coronary syndromes,
and heart failure. In clinical trials,β-blockers have been shown to lead to
long-term improvement in left ventricular function, slowing the pro-
gression of heart failure, and increasing life expectancy [12]. Paradoxi-
cally, although β-blockers may result in pharmacologically induced CI,
they may have a less detrimental effect on exercise capacity and may
even improve exercise performance. Dobre et al. found that a CI b 0.6e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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β-blocker therapy in the HF-ACTION trial [13].
Wilkoff et al. [14] used expired gas analysis to more objectively
evaluate CI on the basis of the relationship betweenHRand oxygen con-
sumption (VO2) during exercise. In this approach, the metabolic
chronotropic relationship (MCR; also known as the chronotropic
index) is calculated from the ratio of the HR reserve to the metabolic
reserve during submaximal exercise. The advantage of using MCR is
that it adjusts for age, physical ﬁtness, and functional capacity and
appears to be unaffected by the exercise testing mode or protocol.
This is accomplished using the following formula, in which metabolic
equivalents (METS) = VO2 (in mL·kg−1·min−1)/3.5:
Estimated HRstage ¼ 220− age – HRrestð Þ½ 
 METSstage − 1
 
=METSpeak − 1
h i
þ HRrest
The aims of the present study were to evaluate changes in HR
response during cardiopulmonary exercise testing (CPET) in patients
undergoing cardiac rehabilitation, using MCR values calculated using
the Wilkoff model, and to assess the effects of β-blockers.
2. Methods
2.1. Subjects
We obtained data on 375 cases of CPET for performing ambulatory
cardiac rehabilitation between January 2011 and December 2012 at
the University of Tokyo Hospital. Patients were excluded, if: (a) they
were not in sinus rhythm, (b) they were b45 years of age or N85 years
of age, (c) they were heart transplant recipients, (d) they had a ventric-
ular assist device, (e) they had a severe illness other than heart disease
such as malignant tumors, and (f) they were unable to achieve an
adequate pedal rotation speed and patients with maximum respiratory
exchange ratio b 1.05. Consequently, a total of 271 exercise tests from
140 patients were included in the ﬁnal analysis. Sixty patients per-
formed CPET once, 40 performed CPET twice, and 40 performed CPET
more than twice. Standard echocardiographic imaging was performed
for evaluation of left ventricular ejection function (LVEF) and assess-
ment of right ventricular systolic pressure (RVSP). The B-type natriuret-
ic peptide (BNP) level was measured prior to CPET. Informed consent
was obtained from each patient and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.
2.2. Cardiopulmonary exercise testing
Symptom-limited CPET was performed on an electromagnetically
braked upright cycle ergometer (Corival, Load, Holland) with a meta-
bolic gas analyzer (AE-300S, Minato Medical Science, Osaka, Japan).
After 4 min of rest on the cycle ergometer, exercise was commenced
at 20 W for a 4-min warm-up, and then the work rate was increased
by 1-W every 6 s. During CPET, blood pressure was measured by an au-
tomatic indirect cuff manometer (FB-300, FukudaDenshi, Tokyo, Japan)
every min. HR and electrocardiography (ECG) weremonitored using an
exercise electrocardiogram (ML-9000, Fukuda Denshi, Tokyo, Japan)
[15]. The criteria for discontinuation of CPET were (i) if pedal rotations
were delayed, (ii) if the patient reached maximum symptom-limited
performance determined by a Borg score of ≥17, (iii) when 85% of
age-predictedmaximal HR (APMHR)was achieved, (iv) if therewas ev-
idence of ST-T changes in ECG, or if any cardiac event such as arrhythmia
or chest pain occurred. Expired gasesweremeasured continuously in all
subjects on a breath-by-breath basis. The anaerobic threshold (AT) was
determined by gas exchange criteria as the point of nonlinear increase
in ventilation equivalents for oxygen. The mean VO2 and HR at warm-
up (Wu; 3–4 min after exercise commenced), at AT, at the respiratorycompensation point (Rc), and at the exercise peak (Pk) were all mea-
sured and recorded.
2.3. Deﬁnition of chronotropic incompetence
The patients who failed to achieve 80% APMHR were classiﬁed as
having CI. Patients who achieved ≥80% of APMHR were classiﬁed as
having chronotropic competence (CC). APMHR was calculated as 220
minus age in years and ΔHR was deﬁned as the difference between
the peak HR and the resting HR [16]. HR reserve (HRR) was calculated
as the difference between APMHR and the resting HR, and the percent
HR reserve (%HRR) was deﬁned as the Δ HR divided by HRR [17,18].
The HR recovery was deﬁned as the peak HR minus the HR at 1 min
into the recovery period. These parameters have been widely used to
assess CI in previous studies. The 80 patients who underwent CPET
more than once, those with a higher peak VO2, were selected for the
evaluation of the HR response.
2.4. Criteria and evaluation of chronotropic response (CR)
TheWilkoff model was applied atWu, AT, Rc, and Pk to calculate the
estimated HR at each stage. The ratios of estimatedHRs to themeasured
HRswere calculated asMCR-Wu,MCR-AT,MCR-Rc, andMCR-Pk. In this
model, the MCR-Pk was consistent with the %APMHR.
A total of 211 exercise tests by 80 patients were included to evaluate
the progress of theCRduring cardiac rehabilitation. The 40 patientswho
underwent CPET twice were evaluated by comparing the results of the
ﬁrst test with the second tests and the 40 who underwent CPET more
than twice were evaluated by comparing the results of the ﬁrst test
with themean results of the other tests. Patients who showed a change
in %APMHR from b80% (CI) to ≥80% (CC), were considered to be nor-
malized, and those who showed a change from ≥80% (CC) to b80%
(CI), were considered to be worsening, and all other patients were con-
sidered to be stable (constant CI or CC). Furthermore, any improvement
in the values of≥3 of the 4 parametersMCR-Wu,MCR-AT,MCR-Rc, and
MCR-Pk, was considered to be an improvement in CR. An increase in 2
parameters was considered to be no change in CR, and an increase in
≤1 parameter was considered to be a deterioration in CR.
2.5. Statistical analyses
Statistical signiﬁcance in multiple-group comparison was assessed
using nonrepeated measures one-way analysis of variance, followed
by Tukey's honestly signiﬁcant test. We used an unpaired Student's
t-test for between group comparisons and a paired t-test for within
group analyses. A p value of b0.05 was considered to be statistically
signiﬁcant. Statistical analyses were performed using the SPSS Base
11.0J software.
3. Results
3.1. Baseline characteristics
The indication for CPET at ambulatory cardiac rehabilitation from
140 patients was as follows:myocardial infarction (38.6%), unstable an-
gina (10.0%), angina pectoris (32.9%), cardiacmyopathy (7.1%), valvular
heart disease (2.1%), arrhythmia (5.0%), and others (4.3%). Of the 114
patientswhohad ischemic heart diseases, 99 patients (86.8%) had treat-
ment of percutaneous coronary intervention. There were 140 eligible
patients, of whom 68 (48.6%) had CI. Of the 140 eligible patients, 45
(32.1%) were on optimal medical therapy without β-blockers (non-BB)
and 95 (67.9%) were on optimal medical therapy with β-blockers (on-
BB). Table 1 shows initial CPET parameters for the 140 patients divided
into 4 groups on the basis of CC or CI and on-BB or non-BB. In the CI
group, 59 of 68 patients (86.8%) were on BB and in the CC group, 36 of
72 patients (50%) were on BB. There were signiﬁcant differences in
Table 1
Cardiopulmonary exercise test parameters for 4 groups based on chronotropic competence or incompetence and the presence or absence of β-blockers.
Chronotropic competence
(CC)
Chronotropic incompetence
(CI)
%APMHR 91 ± 8 88 ± 6 71 ± 9**## 69 ± 7**##
β-blocker non-BB on-BB non-BB on-BB
No. (m; f) 36 (23; 13) 36 (28; 8) 9 (7; 2) 59 (52; 7)
Age, years 69.7 ± 7.4 68.1 ± 9.3 65.6 ± 6.7 63.6 ± 10.7*
BMI 23.2 ± 3.5 24.3 ± 3 23.3 ± 3.4 24.5 ± 2.9*
DM, no.(%) 9 (25) 15 (42) 3 (33) 23 (39)
BNP, pg/ml 66.0 ± 104.6 81.2 ± 73.2 74.7 ± 64.2 115.8 ± 121.5**
HR rest, bpm 75.2 ± 10.9 72.9 ± 10.9 65.6 ± 9**# 66.4 ± 10.7**#
HR peak, bpm 136.0 ± 12 133.3 ± 9.8 110.2 ± 13.3**## 107.8 ± 12.3**##
HR recovery, bpm 27.23 ± 12.9 29.0 ± 8.8 21.0 ± 7.2# 21.7 ± 9.5**##
ΔHR, bpm 60.8 ± 14.6 60.4 ± 13.2 44.7 ± 13.2**## 41.4 ± 12.2**##
%HR reserve 81 ± 1.7 76 ± 1.2 50 ± 1.3**## 46 ± 1.1**##
VO2Pk, ml/min 1117.3 ± 431 1196.6 ± 299.4 1064.8 ± 274.5 1059.9 ± 353.2
VO2Pk/kg, ml/min/kg 18.0 ± 5.0 18.2 ± 3.6 16.7 ± 4.5 15.6 ± 3.7**##
AT, ml/kg/min 12.76 ± 2.69 12.05 ± 2.12 11.95 ± 2.2 11.06 ± 1.93**
MCR-Wu 0.87 ± 0.05 0.87 ± 0.06 0.78 ± 0.07**## 0.77 ± 0.07**##
MCR-AT 0.86 ± 0.07 0.85 ± 0.06 0.73 ± 0.08**## 0.73 ± 0.08**##
MCR-Rc 0.88 ± 0.07 0.84 ± 0.06** 0.72 ± 0.08**## 0.70 ± 0.08**##
MCR-Pk 0.91 ± 0.08 0.88 ± 0.06 0.71 ± 0.09**## 0.69 ± 0.07**##
LVEF, % 68.0 ± 9.3 60.3 ± 11.0** 66.2 ± 11.3 55.9 ± 14.8**
RVSP, mm Hg 20.0 ± 11.7 23.4 ± 9.0 24.1 ± 9.9 26.5 ± 12.7**
Data are presented as means (SD) or No. (%), ⁎⁎p b 0.01 vs. CC/non-BB; ⁎p b 0.05 vs. CC/non-BB; ##p b 0.01 vs. CC/on-BB; #p b 0.05 vs. CC/on-BB; p b 0.05 CC/non-BB vs. CC/on-BB.
BB,β-blockers; non-BB, absence ofβ-blockers; on-BB, presence ofβ-blockers; APMHR, percentage of age-predictedmaximal heart rate;No. (m; f), number of patients (male; female); BMI,
bodymass index; DM, diabetes mellitus; BNP, brain natriuretic peptide; HR, heart rate; bpm, beats per minute; HR rest, heart rate at rest; HR peak, heart rate at the peak;ΔHR, difference
between peak and rest heart rates; VO2Pk, peak oxygen consumption; VO2Pk/kg, peak exercise oxygen consumption per body weight; Wu, warm-up; AT, anaerobic threshold; Rc, respi-
ratory compensation; Pk, peak; LVEF, left ventricular ejection fraction; RVSP, right ventricular systolic pressure.
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tween the CC/non-BB andCI groups.Moreover, therewere signiﬁcant dif-
ferences in resting HR, peak HR, HR recovery, ΔHR, %HRR, peak VO2/kg,
MCR-Wu, MCR-AT, and MCR-Rc between the CC/on-BB group and the
CI/on-BB group.
3.2. Relationship between CI, BNP, and β-blockers
The patients were divided into 4 groups on the basis of BNP
[BNP ≥ 80 (H-BNP) and BNP b 80 (L-BNP)] and on-BB or non-BB
(Table 2). Compared with the L-BNP/non-BB group, the H-BNP/non-BBTable 2
Cardiopulmonary exercise test parameters for 4 based on BNP ≥ 80 and BNP b 80 and the pres
L-BNP (b80)
β-blockers non-BB on-BB
No. (m; f) 33(22;11) 58(50;8)
Age, years 67.8 ± 6.9 65 ± 10.4
BMI 23.6 ± 3.6 24.2 ± 2.7
DM, no.(%) 8 (24) 22 (38)
BNP 31.0 ± 21.2 40.9 ± 19
HR rest, bpm 74.9 ± 10.6 68.8 ± 9.4
HR peak, bpm 134.0 ± 15 120.2 ± 1
HR recovery, bpm 28.0 ± 12.8 26.2 ± 9.2
ΔHR, bpm 59.1 ± 15.2 51.4 ± 14
%HR reserve 77 ± 20 60 ± 16**
VO2Pk, ml/min 1175.1 ± 402.1 1199.1 ±
VO2Pk/kg, ml/min/kg 18.6 ± 5.0 17.9 ± 3.5
AT, ml/kg/min 12.9 ± 2.7 11.9 ± 1.9
MCR-Wu 0.87 ± 0.06 0.82 ± 0.0
MCR-AT 0.85 ± 0.08 0.79 ± 0.0
MCR-Rc 0.86 ± 0.08 0.77 ± 0.0
MCR-Pk 0.88 ± 0.10 0.78 ± 0.0
LVEF, % 66.2 ± 10.4 61.1 ± 12
RVSP, mm Hg 20.2 ± 11.2 24.7 ± 9.4
Data are presented asmeans (SD) or N (%), **p b 0.01 vs. L-BNP/non-BB; *p b 0.05 vs. L-BNP/non
H-BNP/on-BB; p b 0.05 H-BNP/non-BB vs. H-BNP/on-BB.
BB, β-blockers; non-BB, absence of β-blockers; on-BB presence of β-blockers; No. (m; f), numbe
triuretic peptide; HR, heart rate; bpm, beats per minute; HR rest, heart rate at rest; HR peak, hea
consumption; VO2Pk/kg, peak exercise oxygen consumption per body weight; Wu, warm-up; A
tion fraction; RVSP, right ventricular systolic pressure.group showed signiﬁcant differences in peak HR, HR recovery, peak
VO2, peak VO2/kg, and MCR-Wu. Compared with the L-BNP/on-BB
group, the H-BNP/on-BB group showed signiﬁcant differences in peak
VO2, AT, and LVEF. There were signiﬁcant differences in peak HR,
%HRR, AT, MCR-AT, MCR-Rc, MCR-Pk, and LVEF between the non-BB
and on-BB groups for both L-BNP and H-BNP.
The changes in VO2 and the MCR values at each stage are shown in
Fig. 1A and B. VO2 in the L-BNP/on-BB group was higher than in the
H-BNP/on-BB group at AT, Rc, and Pk, whereas VO2 in the L-BNP/
non-BB group was higher than in the H-BNP/non-BB group at Rc and
Pk.MCRvalueswere smaller at each stage in the on-BB group comparedence or absence of β-blockers.
H-BNP (≥80)
non-BB on-BB
12(8;4) 37(30;7)
71.8 ± 8.1 65.7 ± 10.6
22.1 ± 2.9 24.7 ± 3.3
4 (33) 16 (43)
156.9 ± 143.2**# 211.8 ± 139.3**##
** 68.7 ± 11.5 69.1 ± 13.8**
4.3** 122.3 ± 16** 113.2 ± 19.6**
21.2 ± 9.0* 22.5 ± 10.5**
.3** 53.6 ± 16.6 44.1 ± 16.6**
69 ± 20 53 ± 22**
348.8 919 ± 353.1**# 974.8 ± 274.7**#
15.5 ± 4.1** 14.5 ± 3.5**
* 11.8 ± 2.2 10.6 ± 2.1**##
7** 0.82 ± 0.08* 0.79 ± 0.10**
8** 0.81 ± 0.11 0.74 ± 0.11**
8** 0.82 ± 0.12# 0.72 ± 0.12**
9** 0.83 ± 0.13 0.74 ± 0.14**
.7* 69.9 ± 6.5# 52.3 ± 13.2**##
* 22.8 ± 12.0 26.3 ± 14.0**
-BB; ##p b 0.01 vs. L-BNP/on-BB; #p b 0.05 vs. L-BNP/on-BB; p b 0.01 H-BNP/non-BB vs.
r of patients (male; female); BMI, bodymass index; DM, diabetes mellitus; BNP, brain na-
rt rate at the peak;ΔHR, difference between peak and rest heart rates; VO2Pk, peak oxygen
T, anaerobic threshold; Rc, respiratory compensation; Pk, peak; LVEF, left ventricular ejec-
Fig. 1. Changes in oxygen consumption (A) andMCR values (B) at each stage for 4 groups based on BNP≥ 80 and BNP b 80 and the presence or absence of β-blockers. Values of *p b 0.05
and **p b 0.01were considered statistically signiﬁcant. The signiﬁcant difference (B) is shown inTable 2.Wu,warming up; AT, anaerobic threshold; Rc, respiratory compensation; Pk, peak;
BB, β-blockers; non-BB, absence of β-blockers; on-BB, presence of β-blockers; BNP, brain natriuretic peptide; H-BNP, high BNP group with BNP ≥ 80; L-BNP, low BNP group with BNP b 80.
15N. Takano et al. / IJC Heart & Vasculature 6 (2015) 12–18with the non-BB group, particularly compared with the H-BNP/on-BB
group. Regardless of BNP levels, MCR values in the non-BB group de-
creased from Wu to AT and increased after AT (MCR-AT b MCR-Rc),
whereas MCR values in the on-BB group decreased fromWu to Rc and
increased after Rc (MCR-AT NMCR-Rc).
3.3. Classiﬁcation based on an MCR-Wu
The patients were divided into 4 groups based on an impaired CR
(ICR group) with an MCR-Wu b0.8, or a normal CR (NCR group) with
an MCR-Wu ≥0.8, and on-BB or non-BB (Table 3). Compared with the
NCR/non-BB group, the ICR group showed signiﬁcant differences in
peak HR, ΔHR, %HRR, peak VO2, peak VO2/kg, and MCR values at all
stages. Compared with the NCR/on-BB group, the ICR/on-BB group
showed signiﬁcant differences in resting HR, peak HR, ΔHR, %HRR,
peak VO2, peak VO2/kg, AT, MCR-AT, MCR-Rc, MCR-Pk, and RVSP.
Furthermore, there were signiﬁcant differences in peak HR, %HRR,Table 3
Cardiopulmonary exercise test parameters for 4 groups based on MCR-Wu ≥ 0.8 or MCR-Wu b
NCR [MCR-Wu ≥ 0.8]
β-blockers non-BB on-BB
No. (m; f) 36(27;9) 51(44;7)
Age, years 69.5 ± 7.4 65.4 ± 10
BMI 23.3 ± 3.4 24.6 ± 3.2
DM, no.(%) 10(28) 23(45)
BNP, pg/ml 66.1 ± 104.8 76.1 ± 64
HR rest, bpm 74.4 ± 10.8 72.2 ± 10
HR peak, bpm 134.4 ± 14.0 126.4 ± 1
HR recovery, bpm 26.3 ± 12.0 26.0 ± 10
ΔHR, bpm 60.0 ± 14.6 54.2 ± 15
%HR reserve 79.7 ± 18.8 66.3 ± 17
VO2Pk, ml/min 1163.2 ± 419.3 1226.6 ±
VO2Pk/kg, ml/min/kg 18.4 ± 5.0 18.1 ± 3.4
AT, ml/kg/min 12.8 ± 2.7 12.0 ± 2.0
MCR-Wu 0.88 ± 0.05 0.87 ± 0.0
MCR-AT 0.87 ± 0.06 0.83 ± 0.0
MCR-Rc 0.88 ± 0.08 0.81 ± 0.0
MCR-Pk 0.89 ± 0.09 0.82 ± 0.0
LVEF, % 66.7 ± 9.36 59.5 ± 13
RVSP, mm Hg 21.0 ± 11.5 22.7 ± 9.8
Data are presented as means (SD) or N (%), **p b 0.01 vs. NCR/non-BB; *p b 0.05 vs. NCR/non-
#p b 0.05 ICR/non-BB vs. ICR/on-BB.
NCR, normal chronotropic response with an MCR-Wu ≥ 0.8; ICR, impaired chronotropic respo
presence ofβ-blockers; No. (m; f), number of patients (male; female); BMI, bodymass index; D
HR rest, heart rate at rest; HRpeak, heart rate at thepeak;ΔHR, difference between peak and rest
per body weight; Wu, warm-up; AT, anaerobic threshold; Rc, respiratory compensation; Pk, peMCR-AT, MCR-Rc, MCR-Pk, and LVEF between the NCR/non-BB and
NCR/on-BB groups, as well as in BNP, MCR-Rc, and LVEF between the
ICR/non-BB and ICR on-BB groups.
HR and VO2 for each group at each stage are shown in Fig. 2A and B.
In Fig. 2A, HR increases almost linearly at each stage. HR acceleration
slope in the ICR group was less steep than that in the NCR group and
the peak HR in the ICR group was lower than that in the NCR group
for both the non-BB and on-BB groups. The HR acceleration slope in
the on-BB group was less steep than that in the non-BB group for both
ICR andNCR (Fig. 2A). VO2 at AT, Rc, and Pk in theNCR groupwas higher
in the NCR group than in the ICR group for both the non-BB and on-BB
groups (Fig. 2B).
Changes in MCR values for the 4 groups divided on the basis of NCR
or ICR and non-BB or on-BB are shown in Fig. 2C. In the non-BB group,
MCR values decreased from Wu to AT and increased after AT (MCR-
AT bMCR-Rc). Conversely, in the on-BB group MCR values decreased
fromWu to Rc and tended to increase after Rc (MCR-AT NMCR-Rc).0.8 and the presence or absence of β-blockers.
ICR [MCR-Wu b 0.8]
non-BB on-BB
9(3;6) 44(36;8)
* 66.2 ± 7.3 65.1 ± 10.9*
* 23.0 ± 3.8 24.2 ± 2.6
2(22) 15(34)
.8 74.3 ± 62.9 131.7 ± 133.6**#
.6 68.8 ± 11.8 65.1 ± 10.8**$$
3.6** 116.7 ± 16.2** 107.1 ± 14.2**$$
.0 25.1 ± 13.5 23.2 ± 9.5
.0 47.9 ± 16.9** 42.1 ± 14.0**$$
.0** 56.7 ± 16.3** 47.0 ± 15.2**$$
332.1 881.2 ± 222.7**$$ 978.5 ± 298.1**$$
15.1 ± 3.4**$ 14.8 ± 3.6**$$
11.8 ± 2.2 10.7 ± 1.9**$$
4 0.76 ± 0.06**$$ 0.74 ± 0.06**$$
6** 0.72 ± 0.08**$$ 0.70 ± 0.07**$$
6** 0.75 ± 0.09**$ 0.69 ± 0.09**$$#
9** 0.76 ± 0.11** 0.69 ± 0.10**$$
.22** 69.1 ± 10.5$ 55.2 ± 13.8**##
21.0 ± 11.3 28.7 ± 12.6**$
BB; $$p b 0.01 vs. NCR/on-BB; $p b 0.05 vs. NCR/on-BB; ##p b 0.01 ICR/non-BB vs. ICR/on-BB;
nse group with an MCR-Wu b 0.8; BB, β-blockers; non-BB, absence of β-blockers; on-BB
M, diabetesmellitus; BNP, brain natriuretic peptide; HR, heart rate; bpm, beats perminute;
heart rates; VO2Pk, peak oxygen consumption;VO2Pk/kg, peak exercise oxygen consumption
ak; LVEF, left ventricular ejection fraction; RVSP, right ventricular systolic pressure.
Fig. 2. Changes in heart rate (A), oxygen consumption (B), and MCR values (C) at each stage for 4 groups based on NCR or ICR and the presence or absence of β-blockers. Linear approx-
imation in heart rate (A) i.e., NCR/non-BB; y= 15.1x+ 60.1, NCR/on-BB; y= 13.7x+ 58.4, ICR/non-BB; y= 11.9x+ 58.1, ICR/on-BB; y= 10.5x+ 55.6. Values of *p b 0.05 and **p b 0.01
were considered statistically signiﬁcant. The signiﬁcant difference (C) is shown in Table 4.Wu,warm-up; AT, anaerobic threshold; Rc, respiratory compensation; Pk, peak; BB, β-blockers;
non-BB, absence of β-blockers; on-BB, presence of β-blockers; NCR, normal chronotropic response with an MCR-Wu ≥ 0.8; ICR, impaired chronotropic response with an MCR-Wu b 0.8.
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Of the 80 patients selected to evaluate the progress of CR, 29 (36.2%)
were in the non-BB group and 51 (63.8%) were in the on-BB group
(Table 4). Both peak VO2 and AT increased in 47 patients (58.8%), 31
of whom were on BB (66.0%). Of the 47 patients who showed an in-
crease in both peak VO2 and AT, CI was normalized in 8 (7 of these 8
[87.5%] were on BB), and 32 patients (23 of these 32 [71.9%] were on
BB) showed an improvement in CR according to the criteria stipulated
in the present study. In 22 patients, CI wasmaintained regardless of im-
provement in VO2 and AT, but 14 of them did show an improvement in
CR (12 of these 14 [85.7%] were on BB; data not shown). Fig. 3 showsTable 4
Progress of exercise tolerance capacity and heart rate responses throughout cardiac rehabilitat
Chronotropic incompetence
AT Peak VO2 CI→ CC CC→ CI CC→ CC C
↑ ↑ 8 [7] 3 [1] 14 [4] 2
↓ ↑ 2 [2] 0 6 [5] 6
↑ ↓ 0 1 [0] 0 3
↓ ↓ 1 [0] 3 [2] 6 [2] 5
CR Improvement 11 [9] 0 17 [8] 1
Deterioration 0 6 [2] 6 [2] 1
No change 0 1 [1] 3 [1] 3
Total no. 11 [9] 7 [3] 26 [11] 3
[No. on-BB].
AT, anaerobic threshold; Peak VO2, peak oxygen consumption; CI, chronotropic incompetence;changes in MCR values during cardiac rehabilitation. MCR values
increased overall, particularly in the on-BB group.
4. Discussion
4.1. Staging of CI assessment
Both BNP and peak VO2 are strong predictors of mortality in patients
with CHF [18,19]. Our ﬁndings that theH-BNP group hadmore severe CI
and lower peak VO2 and AT comparedwith the L-BNP group are not un-
expected and support the results of previous studies. The ﬁnding that
MCR-Wu and MCR-AT in the CI group were signiﬁcantly smaller thanion.
Chronotropic response Total no.
I→ CI Improvement Deterioration No change
2 [19] 32 [23] 11 [6] 4 [2] 47 [31]
[3] 10 [6] 3 [3] 1 [1] 14 [10]
[2] 0 3 [2] 1 [0] 4 [2]
[4] 5 [2] 9 [6] 1 [0] 15 [8]
9 [14] – – – 47 [3]
4 [13] – – – 26 [1]
[1] – – – 7 [3]
6 [28] 47 [31] 26 [17] 7 [3] 80[51]
CR, chronotropic response; No., number of patients; on-BB, presence of β-blockers.
Fig. 3. Changes in MCR values during cardiac rehabilitation. Data are presented as means
(SE), and p values were determined from paired t-tests. A value of *p b 0.05 was consid-
ered statistically signiﬁcant. Wu, warm-up; AT, anaerobic threshold; Rc, respiratory
compensation; Pk, peak; BB, β-blockers; non-BB, absence of β-blockers; on-BB, presence
of β-blockers.
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during the early stages of exercise. The classiﬁcation based on an MCR-
Wu of 0.8 clearly reﬂects the difference in peak HR and VO2. These
results support the hypothesis that CI can be assessed during the early
stages of exercise.
In the present study, only cases that could be adequately and safely
examined on the basis of a respiratory exchange ratio (RER) of ≥1.05
were selected. However, in the clinical setting of cardiac rehabilitation
for patients with a history of heart disease, sometimes they perform
CPET to determine AT in order to prescribe an appropriate exercise
regimen. In that setting, the maximum measured VO2 is not always
the maximum VO2 obtained by pushing the patient to the limits of
their exercise ability. This may be one of the reasons that the evaluation
of the HR response and CI are often overlooked in clinical practice, and
may explain why it is difﬁcult to establish a standardized quantitative
deﬁnition of CI. Therefore, the ﬁnding that CI can be evaluated during
the early to middle stages of exercise, rather than at the maximum
load stage, is important for the clinical assessment of CI.4.2. Relationship between MCR-AT and MCR-Rc
Exercise under load after AT activates sympathetic nerve activity;
therefore it was assumed that autonomic nervous system balance
could be demonstrated by comparing MCR-AT and MCR-Rc. Indeed, in
the non-BB group, the ratio of measured HR to estimated HR, i.e., MCR
values, increased after AT with MCR-AT bMCR-Rc, whereas in the on-
BB group, MCR values after AT remained low, with MCR-AT NMCR-Rc.
Witte et al. demonstrated that patients with CI did have reduced exer-
cise capacity, but the slope of HR to peak VO2 was the same for patients
with and without CI [19]. Jorde et al. showed that exercise time was
shorter and the HR acceleration slope was less steep in subjects
with CI, irrespective of β-blocker use. Furthermore, a measure of post-
synaptic β-receptor sensitively to norepinephrinewas lower in subjects
with CI [20]. The differences in MCR values found in the present study
may reﬂect the HR response when under the inﬂuence of β-blockers,
inhibiting the rise of catecholamine levels or decreasing sympathetic
tone up to the Rc stage. The novel aspect of this study is that the evalu-
ation of the HR response at speciﬁc stages was deﬁned by metabolic
change, and not by the duration of exercise. This enabled the assess-
ment of differences in the HR response according to the presence or
absence of β-blockers.4.3. Effectiveness of cardiac rehabilitation
In the present study, 47 patients (58.7%) showed an improvement in
peak VO2 and AT during cardiac rehabilitation, and most of them with
an improved HR response also showed an improvement in peak VO2.
The HR response is related to the severity of heart failure; therefore CI
may be not only a cause of the reduction in exercise capacity in patients
with CHF but also an indicator of autonomous nervous system dysfunc-
tion resulting from cardiac disease. Witte et al. supported the concept
that chronotropy is not a major factor in determining exercise capacity
in patients with CHF [19], suggesting that HR limitation is unlikely to be
the cause, but rather the consequence, of exercise intolerance in CHF pa-
tients [21]. Fukuda et al. demonstrated that CHF patients with impaired
exercise capacity had attenuated increments in cardiac output during
exercise [22].
Using conventional evaluation methods, CI showed no change in 62
(77.5%) of the patients in the present study. However, according to the
evaluation criteria stipulated in the present study, 73 patients showed
subtle changes in CR. Throughout the course of cardiac rehabilitation,
we found a signiﬁcant improvement in CR related to β-blocker adminis-
tration. Therefore,β-blockersmay in fact contribute to the improvement
in CR by protecting the myocardium from the cardiotoxic effects of
increased catecholamine levels and by restoration of down-regulated
β1 receptors. In addition, endurance exercise training may improve
chronotropic function in patientswith CHF, probably by increasing baro-
reﬂex sensitivity and reducing sympathetic outﬂow and plasma levels of
neurohormones [23].
4.4. Limitations
There are several limitations to the present study. The study popula-
tion was relatively small and there was no control group. The disease
severity in our patients was mild, and the New York Heart Association
classiﬁcation was low. Because the participation of the study patients
in ambulatory cardiac rehabilitation was voluntary, the frequency and
intensity of the execution varied amongpatients.We did not have infor-
mation on death rates, cause of death, or hospitalization.
5. Conclusions
An attenuated HR response may occur during the early stages of
exercise because theMCR-Wu andMCR-AT in the CI group were signif-
icantly smaller than those in the CC group. In the non-BB group, MCR
values decreased from Wu to AT and increased after AT with MCR-
AT b MCR-Rc. Conversely, in the on-BB group, MCR values decreased
from Wu to Rc and tended to increase after Rc with MCR-AT N MCR-
Rc. The differences in MCR values between the non-BB group and the
on-BB group may reﬂect the HR response under β-blocker administra-
tion. Cardiac rehabilitation increased both peak VO2 and AT with an
improvement in CR, particularly in the on-BB group.
Here, we have presented a method for evaluating CI objectively
using widely available exercise testing methods and standardized
deﬁnitions based on the Wilkoff model.
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